Ablynx Advances Ambitions by Partnering with AbbVie and Merck Serono
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 10 (Table of Contents)
Published: 7 Oct-2013
DOI: 10.3833/pdr.v2013.i10.1983 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Belgian biotech Ablynx has secured AbbVie as a partner for ALX-0061, its Nanobody® targeting the interleukin-6 receptor, in a deal potentially worth up to US$840 M, including US$175 M upfront...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS